High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis

References

• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women 1. J Clin Endocrinol Metab 1999;84:165–9
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial 1. J Clin Endocrinol Metab 2001;86:1626–32
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–61
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840–6
   PubMed Web of Science ®Google Scholar
• Farshchian F, Tehrani FR, Amirrasouli H, et al. Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome. Int J Endocrinol Metab 2014;12:e15503
   PubMedGoogle Scholar
• Lee JM, Kim SR, Yoo SJ, et al. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res 2009;37:1803–12
   PubMed Web of Science ®Google Scholar
• Manco M, Fernandez-Real JM, Equitani F, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007;92:483–90
   PubMed Web of Science ®Google Scholar
• López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes 2006;55:2871–5
   PubMed Web of Science ®Google Scholar
• Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007;56:565–70
   PubMed Web of Science ®Google Scholar
• Lu L-F, Yang S-S, Wang C-P, et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009;18:354–9
   PubMed Web of Science ®Google Scholar
• Liu Y, Shao Y, Yu B, et al. Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population. Clin Chem Lab Med 2012;50:1917–22
   PubMed Web of Science ®Google Scholar
• Lu G-W, Wang Q-J, Xia M-M, Qian J. Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients. Peptides 2014;58:60–4
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9
   PubMed Web of Science ®Google Scholar
• Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005;289:E586–90
   PubMed Web of Science ®Google Scholar
• Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1–8
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745–51
   PubMed Web of Science ®Google Scholar
• Garruti G, de Palo R, Rotelli M, et al. Association between follicular fluid leptin and serum insulin levels in nonoverweight women with polycystic ovary syndrome. BioMed Res Int 2014;2014:980429
   PubMed Web of Science ®Google Scholar
• Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007;22:1824–9
   PubMed Web of Science ®Google Scholar
• Gen R, Akbay E, Muslu N, et al. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009;25:241–5
   PubMed Web of Science ®Google Scholar
• Dİkmen E, Tarkun I, Cantürk Z, ÇetInarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol 2011;27:475–9
   PubMed Web of Science ®Google Scholar
• Chan T-F, Chen Y-L, Chen H-H, et al. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007;88:401–5
   PubMed Web of Science ®Google Scholar
• Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 2010;93:880–4
   PubMed Web of Science ®Google Scholar
• Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008;19:406–12
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Madej P, Zdun D, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2012;162:55–61
   PubMed Web of Science ®Google Scholar
• Spanos N, Tziomalos K, Macut D, et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts 2012;5:495–504
   PubMed Web of Science ®Google Scholar
• Plati E, Kouskouni E, Malamitsi-Puchner A, et al. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 2010;94:1451–6
   PubMed Web of Science ®Google Scholar
• Zwirska-Korczala K, Sodowski K, Konturek S, et al. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 2008;59:161–78
   PubMed Web of Science ®Google Scholar
• Jongwutiwes T, Lertvikool S, Leelaphiwat S, et al. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:536–42
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu P. [Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009;34:72–5
   PubMedGoogle Scholar
• Fu H, Qiu Y, Xia M, et al. Spleen-Yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin. J Tradit Chin Med 2014;34:42–7
   PubMed Web of Science ®Google Scholar
• Tarkun İ, Dikmen E, Çetinarslan B, Cantürk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw 2010;21:272–7
   PubMed Web of Science ®Google Scholar
• Güdücü N, Isçi H, Görmüs U, et al. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28:619–23
   PubMed Web of Science ®Google Scholar
• Tsouma I, Kouskouni E, Demeridou S, et al. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol Endocrinol 2014;30:516–19
   PubMed Web of Science ®Google Scholar
• Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515–27
   PubMed Web of Science ®Google Scholar
• Chen M-P, Chung F-M, Chang D-M, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–30
   PubMed Web of Science ®Google Scholar
• Nawrocka J, Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol 2007;23:231–7
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41
   PubMed Web of Science ®Google Scholar
• Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113–26
   PubMed Web of Science ®Google Scholar